Vion Pharmaceuticals, Inc.
http://vionpharm.com/home.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vion Pharmaceuticals, Inc.
Finance Watch: NGM Reemerges With $122m During Post-July 4th VC Mega-Round Boom
Private Company Edition: After its acquisition by an investor earlier this year, NGM Bio has raised a $122m series A round, adding to a recent surge in large venture capital financings. Also, Vanqua Bio disclosed $45m in new funding and Renalys completed a $38.4m series A.
Finance Watch: Venture Rounds Trend Toward The High End
Private Company Edition: First quarter data again confirm fewer but larger VC rounds in Q1. Big Q2 rounds include a $132.5m series C round for Endeavor Biomedicines, a $103m series A round for Reunion Neuroscience and Enlaza’s $100m series A.
Finance Watch: Ascendis Spins Out Ophthalmology Firm Eyconis With $150m
Private Company Edition: Publicly held Ascendis outsourced its preclinical AMD program to private Eyconis. Also, Innovation Endeavors revealed a new $630m VC fund and Mirae raised $50m for its first life science fund, while Accent, Comanche and Tr1X each brought in $75m rounds.
One Plus One Equals Three For Calluna
Two early-stage companies have merged to form Calluna Therapeutics, which is targeting immunological diseases and hopes to get to proof of concept by mid-2026.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice